Palliation Clinical stage Cellular therapy Cure Grade 3, 4, or 5 Antibody Drug Conjugate (ADCs) ECOG performance status Recurrence Maintenance chemotherapy TNM staging system Tumor Monoclonal antibody CTACAE Surgical margin Chemotherapy Adjuvant treatment Minimal residual disease (MRD) Pathological stage Checkpoint inhibitor Tyrosine kinase inhibitors (TKIs) Sarcoma performance status Complementary therapy Complete remission Neoadjuvant treatment Maintenance chemotherapy Carcinoma Definitive treatment Partial Remission Adenocarcinoma Active surveillance Relapse leukemia Refractory Palliation Clinical stage Cellular therapy Cure Grade 3, 4, or 5 Antibody Drug Conjugate (ADCs) ECOG performance status Recurrence Maintenance chemotherapy TNM staging system Tumor Monoclonal antibody CTACAE Surgical margin Chemotherapy Adjuvant treatment Minimal residual disease (MRD) Pathological stage Checkpoint inhibitor Tyrosine kinase inhibitors (TKIs) Sarcoma performance status Complementary therapy Complete remission Neoadjuvant treatment Maintenance chemotherapy Carcinoma Definitive treatment Partial Remission Adenocarcinoma Active surveillance Relapse leukemia Refractory
(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.
Palliation
Clinical stage
Cellular therapy
Cure
Grade 3, 4, or 5
Antibody Drug Conjugate (ADCs)
ECOG performance status
Recurrence
Maintenance chemotherapy
TNM staging system
Tumor
Monoclonal antibody
CTACAE
Surgical margin
Chemotherapy
Adjuvant treatment
Minimal residual disease (MRD)
Pathological stage
Checkpoint inhibitor
Tyrosine kinase inhibitors (TKIs)
Sarcoma
performance status
Complementary therapy
Complete remission
Neoadjuvant treatment
Maintenance chemotherapy
Carcinoma
Definitive treatment
Partial Remission
Adenocarcinoma
Active surveillance
Relapse
leukemia
Refractory